Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY2328065 in Healthy Men
NCT03427788Phase 1Completed
- Sponsor
- Bayer
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAY2328065 in endometriosis (2 arms), sponsored by Bayer. Primary endpoints: Incidence of treatment-emergent adverse events up to 8 days and Severity of treatment-emergent adverse events up to 8 days. Started Mar 2018; status: completed.
02
Drugs
BAY2328065
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03427788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427788.